Pneumoconiosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Future therapies for [[pneumoconiosis]] are being considered. | |||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Future therapies are being experimented on including inhibiting [[Cytokine|cytokines]] and the use of [[Antioxidant|antioxidants]]. Investigational therapy also includes administration of [[bone marrow]]-derived [[mononuclear cells]]. <ref name="pmid15699791">{{cite journal| author=Rimal B, Greenberg AK, Rom WN| title=Basic pathogenetic mechanisms in silicosis: current understanding. | journal=Curr Opin Pulm Med | year= 2005 | volume= 11 | issue= 2 | pages= 169-73 | pmid=15699791 | doi=10.1097/01.mcp.0000152998.11335.24 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15699791 }} </ref> <ref name="pmid20693250">{{cite journal| author=Maron-Gutierrez T, Castiglione RC, Xisto DG, Oliveira MG, Cruz FF, Peçanha R | display-authors=etal| title=Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis. | journal=Eur Respir J | year= 2011 | volume= 37 | issue= 5 | pages= 1217-25 | pmid=20693250 | doi=10.1183/09031936.00205009 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20693250 }} </ref> <ref name="pmid25723826">{{cite journal| author=Cavalli G, Fallanca F, Dinarello CA, Dagna L| title=Treating pulmonary silicosis by blocking interleukin 1. | journal=Am J Respir Crit Care Med | year= 2015 | volume= 191 | issue= 5 | pages= 596-8 | pmid=25723826 | doi=10.1164/rccm.201412-2150LE | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25723826 }} </ref> In the case of [[berylliosis]], the use of 5-aminosalicylic acid (ASA) is being considered as it improved the [[beryllium]] lymphocyte proliferation test (BeLPT) test by 20% after use for six weeks. <ref name="pmid29080069">{{cite journal| author=Day BJ, Huang J, Barkes BQ, Gillespie M, Li L, Maier LA| title=5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects. | journal=Lung | year= 2018 | volume= 196 | issue= 1 | pages= 103-114 | pmid=29080069 | doi=10.1007/s00408-017-0062-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29080069 }} </ref> The use of tetrandrine, which is found in [[Chinese medicine|Chinese medical]] "han fang ji" has been experimented on and not proven [[effective]]. <ref name="pmid7344866">{{cite journal| author=Li QL| title=[The therapeutic effect of tetrandrine on silicosis (author's transl)]. | journal=Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi | year= 1981 | volume= 4 | issue= 6 | pages= 321-3 | pmid=7344866 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7344866 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 21:23, 28 April 2021
|
Pneumoconiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pneumoconiosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Pneumoconiosis future or investigational therapies |
|
Pneumoconiosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Pneumoconiosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Future therapies for pneumoconiosis are being considered.
Future or Investigational Therapies
Future therapies are being experimented on including inhibiting cytokines and the use of antioxidants. Investigational therapy also includes administration of bone marrow-derived mononuclear cells. [1] [2] [3] In the case of berylliosis, the use of 5-aminosalicylic acid (ASA) is being considered as it improved the beryllium lymphocyte proliferation test (BeLPT) test by 20% after use for six weeks. [4] The use of tetrandrine, which is found in Chinese medical "han fang ji" has been experimented on and not proven effective. [5]
References
- ↑ Rimal B, Greenberg AK, Rom WN (2005). "Basic pathogenetic mechanisms in silicosis: current understanding". Curr Opin Pulm Med. 11 (2): 169–73. doi:10.1097/01.mcp.0000152998.11335.24. PMID 15699791.
- ↑ Maron-Gutierrez T, Castiglione RC, Xisto DG, Oliveira MG, Cruz FF, Peçanha R; et al. (2011). "Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis". Eur Respir J. 37 (5): 1217–25. doi:10.1183/09031936.00205009. PMID 20693250.
- ↑ Cavalli G, Fallanca F, Dinarello CA, Dagna L (2015). "Treating pulmonary silicosis by blocking interleukin 1". Am J Respir Crit Care Med. 191 (5): 596–8. doi:10.1164/rccm.201412-2150LE. PMID 25723826.
- ↑ Day BJ, Huang J, Barkes BQ, Gillespie M, Li L, Maier LA (2018). "5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects". Lung. 196 (1): 103–114. doi:10.1007/s00408-017-0062-x. PMID 29080069.
- ↑ Li QL (1981). "[The therapeutic effect of tetrandrine on silicosis (author's transl)]". Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi. 4 (6): 321–3. PMID 7344866.